Episode
E121: Obinutuzumab in SLE-LN
- Published
- Apr 2, 2025
- Duration seconds
- 1094
- Processing state
not_requested- Canonical source
- https://msputman.podbean.com/e/e121-obinutuzumab-in-sle-ln/
Actions
POST https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e121-obinutuzumab-in-sle-ln/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e121-obinutuzumab-in-sle-ln.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965